Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arteris, Inc. (Nasdaq: AIP) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Arteris describes itself as a global leader in system IP used in semiconductors, and its filings offer formal detail on the financial and operational aspects behind that business.
Among the key documents are current reports on Form 8-K, which Arteris uses to furnish press releases announcing quarterly financial results and other material events. For example, the company has filed 8-Ks referencing press releases on results for quarters ended June 30 and September 30, including metrics such as revenue, licensing and royalty performance, operating loss, and Remaining Performance Obligations. These filings give investors structured insight into how Arteris’ licensing, support and maintenance, and variable royalty revenue streams are evolving.
Users can also review other periodic reports, such as Forms 10-Q and 10-K when available, to understand topics like segment performance, risk factors, and detailed financial statements that complement the high-level figures cited in press releases. For those interested in governance and ownership, SEC filings are the place where proxy statements and beneficial ownership reports would appear.
Stock Titan enhances this information by pairing real-time updates from EDGAR with AI-powered summaries that highlight the main points of lengthy filings. Instead of reading every line of a multi-page 10-K or 10-Q, users can rely on AI explanations to quickly identify revenue trends, key risks, and notable changes. The platform also surfaces insider transaction reports on Form 4 when filed, helping investors monitor trading activity by Arteris officers and directors.
By using this page, investors and researchers can efficiently navigate Arteris’ official SEC disclosures, from earnings-related 8-Ks to comprehensive annual and quarterly reports, supported by AI tools that make complex documents easier to interpret.
AIP filing a Form 144 notice reporting proposed sales of 90,000 shares of Common stock and a series of recent 10b5-1 dispositions. The excerpt lists multiple sale dates and amounts, including 106,031 and 73,610 shares on March and February 2026.
Arteris, Inc. Chief Operating Officer Laurent R. Moll executed an open-market sale of common stock. On April 14, 2026, he sold 13,448 shares at a weighted average price of $20.0313 per share in multiple transactions.
After this sale, he directly holds 265,530 shares of Arteris common stock. The transaction was carried out under a Rule 10b5-1 trading plan that he adopted on March 12, 2026, indicating the sales were pre-scheduled rather than opportunistic. Individual trade prices ranged from $19.90 to $20.22 per share.
Arteris, Inc. director Raman Chitkara sold shares in an open-market transaction. On this date, he sold 5,000 shares of common stock at a weighted average price of $20.0508 per share, with individual sale prices ranging from $20.00 to $20.13. After the sale, he directly holds 152,867 shares, indicating the transaction represents a small portion of his overall position.
Arteris, Inc. Chief Operating Officer Laurent R. Moll reported small open-market sales of company stock under a pre-set trading plan. He sold a total of 1,993 shares of common stock at a weighted average price around $19.90 per share and continues to hold 278,979 shares directly.
Laurent Moll reported securities transactions via a Form 144, listing Restricted Stock Units and recent sales executed under a 10b5-1 plan. The filing cites an RSU grant dated 03/15/2022 and three sales: 04/02/2026 (5,602 shares, $98,890.99), 04/06/2026 (1,552 shares, $28,292.96), and 04/10/2026 (990 shares, $19,701.00).
AIP notice of proposed sales of Common Stock under Rule 144 and a 10b5-1 plan. The filing lists two recent planned sales: 1,552 shares on 04/06/2026 (value $28,292.96) and 5,602 shares on 04/02/2026 (value $98,890.99).
The record also references Restricted Stock Units dated 03/15/2022 as the source of shares. The filing is a notice of intent to sell and does not itself report completed market transactions.
Arteris, Inc. director, President and CEO K. Charles Janac reported an indirect open-market sale of 70,000 shares of Common Stock at a weighted average price of $19.0398 per share. The shares were sold on April 8, 2026 by Bayview Legacy, LLC, an entity for which Janac serves as manager and has voting and dispositive power.
The sale was executed under a Rule 10b5-1 trading plan adopted on March 5, 2025. After the transactions reported, indirect holdings through Bayview Legacy, LLC were 9,119,071 shares, direct holdings were 196,729 shares, and 56,252 shares were held indirectly via the Charles and Lydia Janac Trust, for which Janac serves as trustee.
Bayview Legacy, LLC, a ten percent owner of Arteris, Inc., reported an open-market sale of 70,000 shares of Arteris common stock. The sale occurred on April 8, 2026 at a weighted average price of $19.0398 per share, with individual trade prices ranging from $18.67 to $19.43.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025 by K. Charles Janac, the manager of Bayview Legacy, LLC. Following the sale, Bayview Legacy, LLC indirectly held 9,119,071 shares of Arteris common stock, over which Janac is deemed to have voting and dispositive power.